Literature DB >> 26013410

Differential expression of the calcium-sensing receptor in the ischemic and border zones after transient focal cerebral ischemia in rats.

Jeong Sook Noh1, Ha-Jin Pak1, Yoo-Jin Shin1, Tae-Ryong Riew1, Joo-Hee Park1, Young Wha Moon2, Mun-Yong Lee3.   

Abstract

G-protein-coupled calcium-sensing receptor (CaSR) has been recently recognized as an important modulator of diverse cellular functions, beyond the regulation of systemic calcium homeostasis. To identify whether CaSR is involved in the pathophysiology of stroke, we studied the spatiotemporal regulation of CaSR protein expression in rats undergoing transient focal cerebral ischemia, which was induced by middle cerebral artery occlusion. We observed very weak or negligible immunoreactivity for CaSR in the striatum of sham-operated rats, as well as in the contralateral striatum of ischemic rats after reperfusion. However, CaSR expression was induced in the ischemic and border zones of the lesion in ischemic rats. Six hours post-reperfusion there was an upregulation of CaSR in the ischemic zone, which seemed to decrease after seven days. This upregulation preferentially affected some neurons and cells associated with blood vessels, particularly endothelial cells and pericytes. In contrast, CaSR expression in the peri-infarct region was prominent three days after reperfusion, and with the exception of some neurons, it was mostly located in reactive astrocytes, up to day 14 after ischemia. On the other hand, activated microglia/macrophages in both the ischemic and border zones were devoid of specific labeling for CaSR at any time point after reperfusion, despite their massive infiltration in both regions. Our results show heterogeneity in CaSR-positive cells within the ischemic and border zones, suggesting that CaSR expression is regulated in response to the altered extracellular ionic environment caused by ischemic injury. Thus, CaSR may have a multifunctional role in the pathophysiology of ischemic stroke, possibly in vascular remodeling and astrogliosis.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Corpus striatum; Endothelial cells; Microglia; Pericytes; Reactive astrocytes; Receptors, calcium-sensing; Stroke; Vascular remodeling

Mesh:

Substances:

Year:  2015        PMID: 26013410     DOI: 10.1016/j.jchemneu.2015.05.001

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  7 in total

1.  CaSR Antagonist (Calcilytic) NPS 2143 Hinders the Release of Neuroinflammatory IL-6, Soluble ICAM-1, RANTES, and MCP-2 from Aβ-Exposed Human Cortical Astrocytes.

Authors:  Anna Chiarini; Ubaldo Armato; Peng Hu; Ilaria Dal Prà
Journal:  Cells       Date:  2020-06-02       Impact factor: 6.600

Review 2.  Danger-Sensing/Patten Recognition Receptors and Neuroinflammation in Alzheimer's Disease.

Authors:  Anna Chiarini; Ubaldo Armato; Peng Hu; Ilaria Dal Prà
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

Review 3.  Effect of Pericytes on Cerebral Microvasculature at Different Time Points of Stroke.

Authors:  Zhong Di; Xin Wu; Wei Xie; Xianming Lin
Journal:  Biomed Res Int       Date:  2021-12-22       Impact factor: 3.411

4.  Molecular mechanisms for the prevention and promoting the recovery from ischemic stroke by nutraceutical laminarin: A comparative transcriptomic approach.

Authors:  Jiefeng Luo; Dingzhi Chen; Biyun Qin; Deyan Kong
Journal:  Front Nutr       Date:  2022-08-24

Review 5.  Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease.

Authors:  Anna Chiarini; Ubaldo Armato; Daisong Liu; Ilaria Dal Prà
Journal:  Front Physiol       Date:  2016-04-26       Impact factor: 4.566

6.  Voltage Dependence of a Neuromodulator-Activated Ionic Current.

Authors:  Michael Gray; Jorge Golowasch
Journal:  eNeuro       Date:  2016-05-12

Review 7.  Family C G-Protein-Coupled Receptors in Alzheimer's Disease and Therapeutic Implications.

Authors:  Ilaria Dal Prà; Ubaldo Armato; Anna Chiarini
Journal:  Front Pharmacol       Date:  2019-10-28       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.